<p>Castle Biosciences, Inc. (NASDAQ:CSTL - 獲取免費報告) 首席財務官 Frank Stokes 於 3 月 3 日星期二出售了 7,000 股 Castle Biosciences 股票。股票的平均售價為 27.44 美元，總交易額為 192,080.00 美元。出售後，首席財務官直接持有公司 52,483 股股票，價值 1,440,133.52 美元。這代表其持股減少了 11.77%。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。</p>
<p>獲取 <strong>Castle Biosciences</strong> 的提醒：</p>
<h2>Castle Biosciences 股票下跌 0.9%</h2>
<p>NASDAQ CSTL 週四下跌 0.26 美元，達到 27.91 美元。該股票交易了 419,929 股，而其平均交易量為 445,124 股。該公司的市值為 8.2976 億美元，市盈率為 -32.84，貝塔值為 1.09。該公司的債務與股本比率為 0.02，速動比率為 5.11，流動比率為 5.26。Castle Biosciences, Inc. 的 12 個月低點為 14.59 美元，12 個月高點為 44.28 美元。該公司的 50 日移動平均價格為 36.41 美元，200 日移動平均價格為 31.38 美元。</p>
<p>Castle Biosciences (NASDAQ:CSTL - 獲取免費報告) 最近於 2 月 26 日星期四發佈了季度財報。公司報告該季度每股收益為 -0.08 美元，超出分析師一致預期的 -0.23 美元，超出幅度為 0.15 美元。該季度公司收入為 8,188 萬美元，而分析師預期為 8,119 萬美元。Castle Biosciences 的淨利潤率為 -7.02%，股本回報率為 -0.89%。作為一個整體，研究分析師預測 Castle Biosciences, Inc. 本財年將發佈 0.44 美元的每股收益。</p>
<h2>Castle Biosciences 的機構交易</h2>
<p>幾家對沖基金和其他機構投資者最近對該公司的持股進行了調整。凱通國際資產管理有限公司在第四季度將其在 Castle Biosciences 的股份增加了 188.3%。凱通國際資產管理有限公司現在擁有 2,099 股公司股票，價值 82,000 美元，此前在上個季度購買了 1,371 股。景順投資有限公司在第四季度將其在 Castle Biosciences 的股份增加了 142.6%。景順投資有限公司現在擁有 135,461 股公司股票，價值 5,269,000 美元，此前在上個季度購買了 79,621 股。麥肯齊金融公司在第四季度將其在 Castle Biosciences 的持股增加了 54.2%。麥肯齊金融公司現在擁有 37,317 股公司股票，價值 1,464,000 美元，此前在上個季度收購了 13,113 股。Empowered Funds LLC 在第四季度將其在 Castle Biosciences 的持股增加了 24.2%。Empowered Funds LLC 現在擁有 121,920 股公司股票，價值 4,743,000 美元，此前在上個季度收購了 23,740 股。最後，XTX Topco Ltd 在第四季度購買了 Castle Biosciences 的新股份，價值約 861,000 美元。對沖基金和其他機構投資者持有公司 92.60% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票分析師最近對該股票發表了評論。BTIG Research 將 Castle Biosciences 的目標價格從 38.00 美元上調至 50.00 美元，並在 12 月 12 日的研究報告中給予該股票 &#34;買入&#34; 評級。羅伯特·W·貝爾德將 Castle Biosciences 的目標價格從 41.00 美元上調至 44.00 美元，並在 2 月 27 日的報告中給予公司 &#34;跑贏大盤&#34; 評級。摩根士丹利在週一的研究報告中將 Castle Biosciences 的評級上調至 &#34;買入&#34;。Canaccord Genuity Group 將 Castle Biosciences 的目標價格從 37.00 美元上調至 50.00 美元，並在 12 月 22 日的研究報告中給予公司 &#34;買入&#34; 評級。最後，Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Castle Biosciences 股票的 &#34;賣出 (d)&#34; 評級。八位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;適度買入&#34;，平均目標價格為 47.57 美元。</p>
<p><strong>閲讀我們關於 CSTL 的最新研究報告</strong></p>
<h2>關於 Castle Biosciences</h2>
<p>(獲取免費報告)</p>
<p>Castle Biosciences, Inc 是一家分子診斷公司，專注於為皮膚病患者開發和商業化預後和診斷測試。該公司的專有基因組檢測組合旨在改善風險評估並指導皮膚癌及其他皮膚相關疾病患者的臨牀決策。通過將基因組數據與先進的統計算法相結合，Castle Biosciences 力求提供可操作的見解，幫助醫生量身定製治療方案和監測策略。</p>
<p>該公司的旗艦測試 DecisionDx-Melanoma 評估皮膚黑色素瘤患者的轉移概率，支持更個性化的監測和治療方法。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Castle Biosciences</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這 4 個簡單步驟 &#34;防止美聯儲&#34; 你的銀行賬户</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Castle Biosciences 嗎？</h2>
<p>在你考慮 Castle Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Castle Biosciences 並不在名單上。</p>
<p>雖然 Castle Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IBBQ

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Castle Biosciences 首席財務官 Frank Stokes 出售了 7,000 股公司股票，平均價格為 27.44 美元，總計 192,080 美元。出售後，他持有 52,483 股，反映出其持股減少了 11.77%。該交易已向美國證券交易委員會（SEC）披露。Castle Biosciences 的股票最近下跌 0.9%，報 27.91 美元，市值為 8.2976 億美元。分析師對該公司的共識評級為 “適度買入”，平均目標價格為 47.57 美元</p>

<p>Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) CFO Frank Stokes sold 7,000 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $27.44, for a total transaction of $192,080.00. Following the sale, the chief financial officer directly owned 52,483 shares of the company's stock, valued at $1,440,133.52. This represents a 11.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Castle Biosciences, Inc. (NASDAQ:CSTL - 獲取免費報告) 首席財務官 Frank Stokes 於 3 月 3 日星期二出售了 7,000 股 Castle Biosciences 股票。股票的平均售價為 27.44 美元，總交易額為 192,080.00 美元。出售後，首席財務官直接持有公司 52,483 股股票，價值 1,440,133.52 美元。這代表其持股減少了 11.77%。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。</p>
</div><p>Get <strong>Castle Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Castle Biosciences</strong> 的提醒：</p>
</div><h2>Castle Biosciences Stock Down 0.9%</h2>
<div class="lb-trans"><h2>Castle Biosciences 股票下跌 0.9%</h2>
</div><p>NASDAQ CSTL traded down $0.26 on Thursday, reaching $27.91. 419,929 shares of the stock traded hands, compared to its average volume of 445,124. The company has a market cap of $829.76 million, a price-to-earnings ratio of -32.84 and a beta of 1.09. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The company has a fifty day moving average price of $36.41 and a 200-day moving average price of $31.38.</p>
<div class="lb-trans"><p>NASDAQ CSTL 週四下跌 0.26 美元，達到 27.91 美元。該股票交易了 419,929 股，而其平均交易量為 445,124 股。該公司的市值為 8.2976 億美元，市盈率為 -32.84，貝塔值為 1.09。該公司的債務與股本比率為 0.02，速動比率為 5.11，流動比率為 5.26。Castle Biosciences, Inc. 的 12 個月低點為 14.59 美元，12 個月高點為 44.28 美元。該公司的 50 日移動平均價格為 36.41 美元，200 日移動平均價格為 31.38 美元。</p>
</div><p>Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.15. The company had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. As a group, research analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Castle Biosciences (NASDAQ:CSTL - 獲取免費報告) 最近於 2 月 26 日星期四發佈了季度財報。公司報告該季度每股收益為 -0.08 美元，超出分析師一致預期的 -0.23 美元，超出幅度為 0.15 美元。該季度公司收入為 8,188 萬美元，而分析師預期為 8,119 萬美元。Castle Biosciences 的淨利潤率為 -7.02%，股本回報率為 -0.89%。作為一個整體，研究分析師預測 Castle Biosciences, Inc. 本財年將發佈 0.44 美元的每股收益。</p>
</div><h2>Institutional Trading of Castle Biosciences</h2>
<div class="lb-trans"><h2>Castle Biosciences 的機構交易</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its stake in Castle Biosciences by 188.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,099 shares of the company's stock worth $82,000 after buying an additional 1,371 shares during the last quarter. Invesco Ltd. raised its stake in Castle Biosciences by 142.6% in the fourth quarter. Invesco Ltd. now owns 135,461 shares of the company's stock valued at $5,269,000 after buying an additional 79,621 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Castle Biosciences by 54.2% in the fourth quarter. Mackenzie Financial Corp now owns 37,317 shares of the company's stock worth $1,464,000 after acquiring an additional 13,113 shares in the last quarter. Empowered Funds LLC boosted its holdings in Castle Biosciences by 24.2% in the fourth quarter. Empowered Funds LLC now owns 121,920 shares of the company's stock worth $4,743,000 after acquiring an additional 23,740 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Castle Biosciences during the fourth quarter worth about $861,000. Hedge funds and other institutional investors own 92.60% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對該公司的持股進行了調整。凱通國際資產管理有限公司在第四季度將其在 Castle Biosciences 的股份增加了 188.3%。凱通國際資產管理有限公司現在擁有 2,099 股公司股票，價值 82,000 美元，此前在上個季度購買了 1,371 股。景順投資有限公司在第四季度將其在 Castle Biosciences 的股份增加了 142.6%。景順投資有限公司現在擁有 135,461 股公司股票，價值 5,269,000 美元，此前在上個季度購買了 79,621 股。麥肯齊金融公司在第四季度將其在 Castle Biosciences 的持股增加了 54.2%。麥肯齊金融公司現在擁有 37,317 股公司股票，價值 1,464,000 美元，此前在上個季度收購了 13,113 股。Empowered Funds LLC 在第四季度將其在 Castle Biosciences 的持股增加了 24.2%。Empowered Funds LLC 現在擁有 121,920 股公司股票，價值 4,743,000 美元，此前在上個季度收購了 23,740 股。最後，XTX Topco Ltd 在第四季度購買了 Castle Biosciences 的新股份，價值約 861,000 美元。對沖基金和其他機構投資者持有公司 92.60% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts recently commented on the stock. BTIG Research boosted their price objective on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, December 12th. Robert W. Baird lifted their price target on Castle Biosciences from $41.00 to $44.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, February 27th. Morgan Stanley upgraded Castle Biosciences to a &#34;buy&#34; rating in a research note on Monday. Canaccord Genuity Group raised their price objective on Castle Biosciences from $37.00 to $50.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, December 22nd. Finally, Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of Castle Biosciences in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $47.57.</p>
<div class="lb-trans"><p>一些股票分析師最近對該股票發表了評論。BTIG Research 將 Castle Biosciences 的目標價格從 38.00 美元上調至 50.00 美元，並在 12 月 12 日的研究報告中給予該股票 &#34;買入&#34; 評級。羅伯特·W·貝爾德將 Castle Biosciences 的目標價格從 41.00 美元上調至 44.00 美元，並在 2 月 27 日的報告中給予公司 &#34;跑贏大盤&#34; 評級。摩根士丹利在週一的研究報告中將 Castle Biosciences 的評級上調至 &#34;買入&#34;。Canaccord Genuity Group 將 Castle Biosciences 的目標價格從 37.00 美元上調至 50.00 美元，並在 12 月 22 日的研究報告中給予公司 &#34;買入&#34; 評級。最後，Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Castle Biosciences 股票的 &#34;賣出 (d)&#34; 評級。八位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;適度買入&#34;，平均目標價格為 47.57 美元。</p>
</div><p><strong>Read Our Latest Research Report on CSTL</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CSTL 的最新研究報告</strong></p>
</div><h2>About Castle Biosciences</h2>
<div class="lb-trans"><h2>關於 Castle Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.</p>
<div class="lb-trans"><p>Castle Biosciences, Inc 是一家分子診斷公司，專注於為皮膚病患者開發和商業化預後和診斷測試。該公司的專有基因組檢測組合旨在改善風險評估並指導皮膚癌及其他皮膚相關疾病患者的臨牀決策。通過將基因組數據與先進的統計算法相結合，Castle Biosciences 力求提供可操作的見解，幫助醫生量身定製治療方案和監測策略。</p>
</div><p>The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.</p>
<div class="lb-trans"><p>該公司的旗艦測試 DecisionDx-Melanoma 評估皮膚黑色素瘤患者的轉移概率，支持更個性化的監測和治療方法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Castle Biosciences</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Castle Biosciences</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這 4 個簡單步驟 &#34;防止美聯儲&#34; 你的銀行賬户</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=CSTL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Castle Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Castle Biosciences 嗎？</h2>
</div><p>Before you consider Castle Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Castle Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Castle Biosciences 並不在名單上。</p>
</div><p>While Castle Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Castle Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Frank Stokes 出售了 7,000 股 Castle Biosciences（NASDAQ:CSTL）的股票